QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer

NCT07733115 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer (BTC)

Interventions

BIOLOGICAL: Iparomlimab and Tuvonralimab (QL1706)
DRUG: Gemcitabine and Cisplatin Chemotherapy

Sponsor

Shanghai Zhongshan Hospital